Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04998201 · ClinicalTrials.gov registry record · Phase 2
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
A Phase 2 study, sponsored by Arrowhead Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 353
- Enrollment target
NCT04998201: Completed Phase 2 study, sponsored by Arrowhead Pharmaceuticals.
NCT04998201 is a Phase 2 study that has completed, run by Arrowhead Pharmaceuticals. The registered enrollment target is 353 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (165% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04998201, a Phase 2 study, has completed, sponsored by Arrowhead Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 353 participants
- Enrollment target
Study Summary
Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standards of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.
Primary Outcome
Least square (LS) mean and standard error (SE) were calculated using mixed model repeated measures (MMRM) which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Interventions
- DRUG Placebo
- DRUG ARO-APOC3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2023-08-14 |
| Phase | Phase 2 |
What the finished NCT04998201 record still lists
NCT04998201 is an interventional study that assigns participants to a tested intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (165% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04998201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04998201 about?
NCT04998201 is a clinical study titled "Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia". Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recom...
What is the current status of trial NCT04998201?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 353 participants. The study started on 2021-09-28. Estimated completion is 2023-08-14.
What interventions are being tested in trial NCT04998201?
The interventions under investigation include: Placebo (DRUG), ARO-APOC3 (DRUG).
Who is sponsoring clinical trial NCT04998201?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04998201's enrollment target sits among peer trials
353 129th of 2000 higher than 1,871 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05548296 · 353 participants · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- NCT05884775 · 353 participants · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI